Assessment of CD40L and TSAB serum level in Graves disease patients.

Q3 Medicine

Human Antibodies Pub Date : 2024-09-23 DOI:10.3233/HAB-240036

Alkhansaa Tariq Jawad, Hayfaa Mahmood Fahad, Ayat Ali Salih

{"title":"Assessment of CD40L and TSAB serum level in Graves disease patients.","authors":"Alkhansaa Tariq Jawad, Hayfaa Mahmood Fahad, Ayat Ali Salih","doi":"10.3233/HAB-240036","DOIUrl":null,"url":null,"abstract":"Background: The autoimmune disorder known as Graves' disease. The condition is due to the binding of thyroid-stimulating immunoglobulins to the thyrotropin receptor located on the thyroid gland. The result is an excess of thyroidal hormones. symptoms of hyperthyroidism, and the formation of diffuse goiter.Objectives: This research intends to quantify the levels of CD40L, TSAB in people who suffer from Graves' disease. It also aims to determine the relationship between TSAB and the duration of the disease, as well as analyze the role of CD40L as a predictive marker for Graves' disease using medcalc Statistical Software version 16.4.3 and SAS (2018).Methods: In a case-control study, randomly selected 90 graves disease patients were included, the randomly selected patients were divided equally and matched into a case group who have graves disease and graves disease-free patients as a control group. For both groups whole blood sample was examined to compare for (TSAB), and (CD40L) levels determination by ELISA technique.Results: The average serum levels of CD40L showed a highly significant correlation (P value < 0.01) among the groups examined for Graves' disease. The patient group consisted of 13 males (28.89%) and 32 females (71.11%). No significant correlation was identified between TSAB and the duration of the condition.Conclusion: Thyroid stimulating antibody (TSAb) test and ultrasonography of the thyroid gland are valuable diagnostic techniques for autoimmune Graves' disease (GD). CD40L could potentially serve as a predictive diagnostic marker for Graves' disease. However, there is no observed link between the duration of the disease and the concentration of TSAB.","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Antibodies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/HAB-240036","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The autoimmune disorder known as Graves' disease. The condition is due to the binding of thyroid-stimulating immunoglobulins to the thyrotropin receptor located on the thyroid gland. The result is an excess of thyroidal hormones. symptoms of hyperthyroidism, and the formation of diffuse goiter.

Objectives: This research intends to quantify the levels of CD40L, TSAB in people who suffer from Graves' disease. It also aims to determine the relationship between TSAB and the duration of the disease, as well as analyze the role of CD40L as a predictive marker for Graves' disease using medcalc Statistical Software version 16.4.3 and SAS (2018).

Methods: In a case-control study, randomly selected 90 graves disease patients were included, the randomly selected patients were divided equally and matched into a case group who have graves disease and graves disease-free patients as a control group. For both groups whole blood sample was examined to compare for (TSAB), and (CD40L) levels determination by ELISA technique.

Results: The average serum levels of CD40L showed a highly significant correlation (P value < 0.01) among the groups examined for Graves' disease. The patient group consisted of 13 males (28.89%) and 32 females (71.11%). No significant correlation was identified between TSAB and the duration of the condition.

Conclusion: Thyroid stimulating antibody (TSAb) test and ultrasonography of the thyroid gland are valuable diagnostic techniques for autoimmune Graves' disease (GD). CD40L could potentially serve as a predictive diagnostic marker for Graves' disease. However, there is no observed link between the duration of the disease and the concentration of TSAB.

查看原文本刊更多论文

评估巴塞杜氏病患者血清中的 CD40L 和 TSAB 水平。

背景：巴塞杜氏病是一种自身免疫性疾病：巴塞杜氏病是一种自身免疫性疾病。这种疾病是由于刺激甲状腺的免疫球蛋白与位于甲状腺上的促甲状腺激素受体结合所致。其结果是甲状腺激素过多，出现甲状腺功能亢进症状，并形成弥漫性甲状腺肿：本研究旨在量化巴塞杜氏病患者体内的 CD40L 和 TSAB 水平。研究还旨在确定TSAB与病程之间的关系，并使用medcalc统计软件16.4.3版和SAS（2018）分析CD40L作为巴塞杜氏病预测标志物的作用：在病例对照研究中，随机选取90例巴塞杜氏病患者作为研究对象，将随机选取的患者平均分为病例组（患有巴塞杜氏病）和对照组（无巴塞杜氏病）。对两组患者的全血样本进行检测，通过酶联免疫吸附法测定（TSAB）和（CD40L）水平：结果：在接受检查的巴塞杜氏病患者组中，CD40L的平均血清水平显示出极显著的相关性（P值<0.01）。患者组中有 13 名男性（28.89%）和 32 名女性（71.11%）。TSAB与病程无明显相关性：结论：促甲状腺抗体（TSAb）检测和甲状腺超声波检查是自身免疫性巴塞杜氏病（GD）的重要诊断技术。CD40L有可能成为巴塞杜氏病的预测性诊断标志物。然而，在疾病的持续时间和TSAB的浓度之间并没有观察到任何联系。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Antibodies Medicine-Immunology and Allergy

CiteScore

3.50

自引率

0.00%

发文量

期刊介绍： Human Antibodies is an international journal designed to bring together all aspects of human hybridomas and antibody technology under a single, cohesive theme. This includes fundamental research, applied science and clinical applications. Emphasis in the published articles is on antisera, monoclonal antibodies, fusion partners, EBV transformation, transfections, in vitro immunization, defined antigens, tissue reactivity, scale-up production, chimeric antibodies, autoimmunity, natural antibodies/immune response, anti-idiotypes, and hybridomas secreting interesting growth factors. Immunoregulatory molecules, including T cell hybridomas, will also be featured.